AI-Driven Personalized Management for Type 2 Diabetes: A 12-Month Quasi-Experimental Study
by Reziwanguli Amuti·Updated 1mo ago
198.1 KB1files
Available on 1 platform
Sign in to view source links and access this dataset
Description
A dataset from a 12-month, multicenter, prospective cohort study evaluating an AI-driven personalized management platform for type 2 diabetes. The study enrolled 1,452 patients between April 2022 and April 2023, with 1,343 completing the trial. The research, authored by Reziwanguli Amuti and published under a CC-BY-4.0 license, compares intervention and control groups on metrics like HbA1c, fasting plasma glucose, BMI, and lipid profiles.
Use Cases
Compare the effectiveness of AI-driven dynamic self-management plans versus routine care based on glycemic control outcomes.
Analyze the relationship between intervention type and diabetes remission rates based on the reported co-primary outcome.
Investigate correlations between Self-Monitoring of Blood Glucose frequency and improvements in clinical metrics like HbA1c and BMI.
Evaluate the impact of a personalized management platform on secondary health indicators such as Urine Albumin-to-Creatinine Ratio and blood lipids.
Strengths
Study includes a substantial cohort of 1,452 enrolled patients with type 2 diabetes.
Provides specific, quantified results for key metrics like HbA1c reduction (1.92% vs. 1.31%) and fasting plasma glucose.
Describes a clear, 12-month prospective study design with intervention and control groups of equal size (n=726 each).
Limitations
The dataset's internal structure (columns, rows) is unknown, requiring manual inspection after download.
Column-level documentation is absent; field semantics must be inferred from the study description.
The data file is a 198.1 KB PDF, suggesting the dataset's scope is limited and may not be in a readily analyzable tabular format.
Provenance
Source
Reziwanguli Amuti via figshare.
Collection Method
Data was collected as part of a 12-month, multicenter, prospective, open-label, quasi-experimental cohort study.
Time Range
Patients were enrolled between April 2022 and April 2023, with the study lasting 12 months.
Freshness
Last updated 2026-05-07 05:44:50; freshness should be verified.
The primary data file is a PDF (198.1 KB), which may require extraction or manual transcription to access structured data.